Chronic obstructive pulmonary disease • 12: New treatments for COPD

Thorax

Volumn 58, Issue 9, 2003, Pages 803-808

  Barnes, P J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 7 [3 [2 CYCLOPROPYLMETHYL 3 METHOXY 4 [(METHYLAMINO)CARBONYL]PHENOXY]PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 PROPANOIC ACID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BIIL 284; BRONCHODILATING AGENT; CORTICOSTEROID; I KAPPA B; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LY 29311; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; SB 201146; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

CELL ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; EMPHYSEMA; GASTROINTESTINAL TOXICITY; HUMAN; MOLECULAR DYNAMICS; NAUSEA; PRIORITY JOURNAL; REVIEW; SEPTICEMIA; SIDE EFFECT; SMOKING CESSATION;

ANTI-INFLAMMATORY AGENTS; FORECASTING; HUMANS; METERED DOSE INHALERS; PROTEASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 0041829113     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.58.9.803     Document Type: Review

References (90)

1. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80.
2. Hogg JC. Chronic obstructive pulmonary disease: an overview of pathology and pathogenesis. Novartis Found Symp 2001;234:4-19.
3. Barnes PJ. New concepts in COPD. Ann Rev Med 2003;54:113-29.
4. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest 2000;117:10-4S.
5. Saetta M, Turato G, Maestrelli P, et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-9.
6. Barnes PJ. New treatments for chronic obstructive pulmonary disease. Curr Opin Pharmacol 2001;1:217-22.
7. Barnes PJ. New treatments for COPD. Nature Rev Drug Disc 2002;1:437-45.
8. Barnes PJ. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:S72-9.
9. Shapiro SD. Animal models for COPD. Chest 2000;117:223-7S.
10. Dawkins PA, Stockley RA. Animal models of chronic obstructive pulmonary disease. Thorax 2001;56:972-7.
11. Hansel TT, Barnes PJ. New drugs for asthma and COPD. Basel: Karger, 2001.
12. Lancaster T, Stead L, Silagy C, et al. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ 2000;321:355-8.
13. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-91.
14. Tashkin DP, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo controlled, randomised trial. Lancet 2001;357:1571-5.
15. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation (Cochrane Review). Cochrane Database Syst Rev 2000;4:CD000031.
16. Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs 2000;59:1007-24.
17. Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457-64.
18. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117:63-6S.
19. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1136-42.
20. Casaburi R, Briggs DDJ, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest 2000;118:1294-302.
21. van Noord JA, Bantje TA, Eland ME, et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000;55:289-94.
22. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
23. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002;19:209-16.
24. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000;55:12-8.
25. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999;160:893-8.
26. Yokomizo T, Kato K, Terawoki K, et al. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000;192:421-32.
27. 4 receptor antagonist LY29311: in vivo pulmonary studies. Naunyn Schmiedebergs Arch Pharmacol 2000;361:397-404.
28. Crooks SW, Bayley DL, Hill SL, et al. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000;15:274-80.
29. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-4.
30. Yang XD, Corvalan JR, Wang P, et al. Fully human anti-interleukin-8 monoclonol antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leuk Biol 1999;66:401-10.
31. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000;18:217-42.
32. Traves SL, Culpitt S, Russell REK, et al. Increased levels of the chemokines GRO-α and MCP-1 in sputum samples from patients with COPD. Thorax 2002;57:590-5.
33. White JR, Lee JM, Young PR, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998;273:10095-8.
34. Hay DWP, Sarau HM. Interleukin-8 receptor antagonists in pulmonary diseases. Curr Opin Pharmacol 2001;1:242-7.
35. de Boer WI, Sont JK, van Schadewijk A, et al. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000;190:619-26.
36. de Godoy I, Donahoe M, Calhoun WJ, et al. Elevated TNF-alpha production by peripheral blood monocytes of weight- losing COPD patients. Am J Respir Crit Care Med 1996;153:633-7.
37. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000;59:1341-59.
38. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999;57:945-66.
39. Barlaam B, Bird TG, Lambert-Van DB, et al. New α-substituted succinate-based hydroxamic acids as TNFα convertase inhibitors. J Med Chem 1999;42:4890-908.
40. Rabinowitz MH, Andrews RC, Becherer JD, et al. Design of selective and soluble inhibitors of tumor necrosis factor-α converting enzyme (TACE). J Med Chem 2001;44:4252-67.
41. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000;162:1175-7.
42. Paredi P, Kharitonov SA, Leak D, et al. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:369-73.
43. Macnee W. Oxidants/antioxidants and COPD. Chest 2000;117:303-17S.
44. Grandjean EM, Berthet P, Ruffmann R, et al. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000;22:209-21.
45. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001;322:1271-4.
46. Cuzzocrea S, Riley DP, Caputi AP, et al. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001;53:135-59.
47. Ichinose M, Sugiura H, Yamagata S, et al. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am J Respir Crit Care Med 2000;160:701-6.
48. Hobbs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol 1999;39:191-220.
49. Erin EM, Hansel TT, Kharitonov SA, et al. A selective inhibitor of inducible nitric axide synthase inhibits exhaled breath nitric oxide. Am J Respir Crit Care Med 2002;165:A187.
50. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23.
51. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-53.
52. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; the ISOLDE trial. BMJ 2000;320:1297-303.
53. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
54. Barnes PJ. Inhaled corticosteroids are not helpful in chronic obstructive pulmanary disease. Am J Respir Crit Care Med 2000;161:342-4.
55. Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.
56. Culpitt SV, Nightingale JA, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635-9.
57. Nightingale JA, Rogers DF, Chung KF, et al. No effect of inhaled budesonide on the response to inhaled ozone in normal subjects. Am J Respir Crit Care Med 2000;161:479-86.
58. Meagher LC, Cousin JM, Seckl JR, et al. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996;156:4422-8.
59. Ito K, Lim S, Caramori G, et al. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001;15:1100-2.
60. Souness JE, Aldous D, Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 2000;47:127-62.
61. Spond J, Chapman R, Fine J, et al. Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. Pulm Pharmacol Ther 2001;14:157-64.
62. Bundschuh DS, Eltze M, Barsig J, et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297:280-90.
63. Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001;358:265-70.
64. Edelson J, Compton CH, Nieman R, et al. Cilomilast (Ariflo) a potent, selective phosphodiesterase 4 inhibitor, reduces exacerbations in COPD patients: results of a 6-month trial. Am J Respir Crit Care Med 2001;163:A771.
65. Timmer W, Leclerc V, Birraux G, et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-α ex vivo. J Clin Pharmacol 2002;42:297-303.
66. Delhase M, Li N, Karin M. Kinase regulation in inflammatory response. Nature 2000;406:367-8.
67. Nasuhara Y, Adcock IM, Catley M, et al. Differential IKK activation and IkBα degradation by interleukin-1β and tumor necrosis factor-α in human U937 monocytic cells: evidence for additional regulatory steps in κB-dependent transcription. J Biol Chem 1999;274:19965-72.
68. Davenpeck KL, Berens KL, Dixon RA, et al. Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro. J Allergy Clin Immunol 2000;105:769-75.
69. Noguera A, Batle S, Miralles C, et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001;56:432-7.
70. Takanashi S, Hasegawa Y, Kanehira Y, et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J 1999;14:309-14.
71. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crahn's disease. Gastroenterology 2000;119:1473-82.
72. Carter AB, Monick MM, Hunninghake GW. Both erk and p38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol 1999;20:751-8.
73. Meja KK, Seldon PM, Nasuhara Y, et al. p38 MAP kinase and MKK-1 cooperate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-κB-independent mechanism. Br J Pharmacol 2000;131:1143-53.
74. Lee JC, Kumar S, Griswold DE, et al. Inhibition of p38 MAP kinase as a therapeulic strategy. Immunopharmacology 2000;47:185-201.
75. Underwood DC, Osborn RR, Bochnowicz S, et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L895-902.
76. Sasaki T, Irie-Sasaki J, Jones RG, et al. Function of P13Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000;287:1040-6.
77. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999;160:S49-52.
78. Shapiro SD, Senior RM. Matrix metalloproteinases. Matrix degradation and more. Am J Respir Cell Mol Biol 1999;20:1100-2.
79. Kawabata K, Suzuki M, Sugitani M, et al. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun 1991;177:814-20.
80. Fujie K, Shinguh Y, Yamazaki A, et al. Inhibition of elastase-induced acute inflammation and pulmonary emphysema in hamsters by a novel neutrophil elastase inhibitor FR901277. Inflamm Res 1999;48:160-7.
81. Punturieri A, Filippov S, Allen E, et al. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J Exp Med 2000;192:789-800.
82. Leung-Toung R, Li W, Tam TF, et al. Thiol-dependent enzymes and their inhibitors: a review. Curr Med Chem 2002;9:979-1002.
83. Russell RE, Culpitt SV, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002;26:602-9.
84. Massaro G, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nature Med 1997;3:675-7.
85. Belloni PN, Garvin L, Mao CP, et al. Effects of all-trans-retinoic acid in promoting alveolar repair. Chest 2000;117:235-41S.
86. Mao JT, Goldin JG, Dermand J, et al. A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am J Respir Crit Care Med 2002;165:718-23.
87. Smith KR. Inaugural article: national burden of disease in India from indoor air pollution. Proc Natl Acad Sci USA 2000;97:13286-93.
88. Barnes PJ. Molecular genetics of chronic obstructive pulmonary disease. Thorax 1999;54:245-52.
89. Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res 2001;2:20-6.
90. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001;163:1693-772.